CBP/p300 bromodomains regulate amyloid-like protein aggregation upon aberrant lysine acetylation
Lysine acetylation is becoming increasingly recognized as a general biological principle in cellular homeostasis, and is subject to abnormal control in different human pathologies. Here, we describe a global effect on amyloid-like protein aggregation in human cells that results from aberrant lysine...
Main Authors: | Olzscha, H, Fedorov, O, Kessler, B, Knapp, S, La Thangue, N |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Cell Press
2016
|
Similar Items
-
Bromodomains control amyloid-like aggregation of aberrantly acetylated proteins
by: Olzscha, H, et al.
Published: (2018) -
Development of selective CBP/P300 benzoxazepine bromodomain inhibitors
by: Popp, T, et al.
Published: (2016) -
Targeting bromodomains: epigenetic readers of lysine acetylation.
by: Filippakopoulos, P, et al.
Published: (2014) -
Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
by: Hay, D, et al.
Published: (2014) -
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
by: Hammitzsch, A, et al.
Published: (2015)